WallStreetZenWallStreetZen

NASDAQ: ABIO
Arca Biopharma Inc Earnings & Revenue

ABIO earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$5.3M
Current Profit Margin
0%

ABIO Return on Equity

Current Company
-13.8%
Current Industry
-63.5%
Current Market
188%
ABIO's Return on Equity (-13.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ABIO announces earnings.

ABIO Return on Assets

Current Company
-13.3%
Current Industry
2.9%
ABIO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABIO Return on Capital Employed

Current Company
-14.34%
Current Industry
19.5%
ABIO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABIO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABIO$0.00-$5.23M-$5.34MN/AN/A
AVRO$0.00$12.64M$12.16MN/AN/A
GANX$55.18k-$22.10M-$22.27M+21.77%N/A
MAIA$0.00-$19.77M-$19.77MN/AN/A
CKPT$103.00k-$51.85M-$51.85M-50.61%N/A

Arca Biopharma Earnings & Revenue FAQ

What were ABIO's earnings last quarter?

On Invalid Date, Arca Biopharma (NASDAQ: ABIO) reported Q4 2023 earnings per share (EPS) of -$0.08, up 0% year over year. Total Arca Biopharma earnings for the quarter were -$1.09 million. In the same quarter last year, Arca Biopharma's earnings per share (EPS) was -$0.08.

If you're new to stock investing, here's how to buy Arca Biopharma stock.

What was ABIO's earnings growth in the past year?

As of Q2 2024, Arca Biopharma's earnings has grown year over year. Arca Biopharma's earnings in the past year totalled -$5.34 million.

What was ABIO's revenue last quarter?

On Invalid Date, Arca Biopharma (NASDAQ: ABIO) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Arca Biopharma's revenue was $0.00.

What was ABIO's revenue growth in the past year?

As of Q2 2024, Arca Biopharma's revenue has grown null year over year. Arca Biopharma's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.